Niraparib Efficacy in Patient With Unresectable Mesothelioma

Phase 2 Completed 88 enrolled University Hospital Southampton NHS Foundation Trust British Lung Foundation · collab University of Southampton · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of niraparib versus active symptom control (ASC) in patients who have relapsed after previously receiving platinum based systemic therapy. 84 patients will be recruited from approximately 10 UK trial network sites.

Timeline

Start: 2022-07-11
Primary completion: 2025-01-31
Completion: 2025-01-31

Publications

Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S, Stuart C, Johnson L, Mallard K, Nye M, Darlison L, Dulloo S, Cave J, Luo JL, Taylor P, Spicer J, Poile C, Bzura A, Griffiths G. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. BMJ Open. 2023 Nov 22;13(11):e073120. doi: 10.1136/bmjopen-2023-073120.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Niraparib	Small molecule	200 mg	Oral
Subject	Niraparib	Small molecule	300 mg	Oral

Niraparib Efficacy in Patient With Unresectable Mesothelioma

Summary

Timeline

Publications

Drugs

Indications